Primary CD34+ CML cells were then treated with 10 μM IM for 72h, and the inhibitory effect of IM on CD34+ CML primary cells was assessed by the P-crkl assay, and K562 cells were used as a positive control. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.